Use of drug-eluting stents in saphenous vein aortocoronary bypass graft lesions: A critical appraisal

Journal of Interventional Cardiology

Volumn 21, Issue 2, 2008, Pages 151-157

  Brilakis, Emmanouil S ^a   Saeed, Bilal ^b   Banerjee, Subhash ^b  

^a VA NORTH TEXAS HEALTH CARE SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; RAPAMYCIN;

ANGIOCARDIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY STENT; DRUG ELUTING STENT; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; REVIEW; SAPHENOUS VEIN GRAFT;

AORTA; CORONARY ANGIOGRAPHY; CORONARY ARTERY BYPASS; DRUG-ELUTING STENTS; HUMANS; SAPHENOUS VEIN; TICLOPIDINE;

EID: 41849121232     PISSN: 08964327     EISSN: 15408183     Source Type: Journal    
DOI: 10.1111/j.1540-8183.2007.00341.x     Document Type: Review

References (40)

1. Kozak LJ, DeFrances CJ, Hall MJ. National hospital discharge survey: 2004 annual summary with detailed diagnosis and procedure data. Vital Health Stat 13 2006 162 : 1 209.
2. Alexander JH, Hafley G, Harrington RA, et al. Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: A randomized controlled trial. JAMA 2005 294 : 2446 2454.
3. Fitzgibbon GM, Kafka HP, Leach AJ, et al. Coronary bypass graft fate and patient outcome: Angiographic follow-up of 5,065 grafts related to survival and reoperation in 1,388 patients during 25 years. J Am Coll Cardiol 1996 28 : 616 626.
4. Goldman S, Zadina K, Moritz T, et al. Long-term patency of saphenous vein and left internal mammary artery grafts after coronary artery bypass surgery results from a Department of Veterans Affairs Cooperative Study. J Am Coll Cardiol 2004 44 : 2149 2156.
5. Morrison DA, Sethi G, Sacks J, et al. Percutaneous coronary intervention versus repeat bypass surgery for patients with medically refractory myocardial ischemia: AWESOME randomized trial and registry experience with post-CABG patients. J Am Coll Cardiol 2002 40 : 1951 1954.
6. Savage MP, Douglas JS Jr., Fischman DL, et al. for the Saphenous Vein De Novo Trial Investigators. Stent placement compared with balloon angioplasty for obstructed coronary bypass grafts. N Engl J Med 1997 337 : 740 747.
7. Hanekamp CE, Koolen JJ, Den Heijer P, et al. Randomized study to compare balloon angioplasty and elective stent implantation in venous bypass grafts: The Venestent study. Catheter Cardiovasc Interv 2003 60 : 452 457.
8. de Jaegere PP, van Domburg RT, Feyter PJ, et al. Long-term clinical outcome after stent implantation in saphenous vein grafts. J Am Coll Cardiol 1996 28 : 89 96.
9. Keeley EC, Velez CA, O'Neill WW, et al. Long-term clinical outcome and predictors of major adverse cardiac events after percutaneous interventions on saphenous vein grafts. J Am Coll Cardiol 2001 38 : 659 665.
10. Kastrati A, Mehilli J, Pache J, et al. Analysis of 14 trials comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007 356 : 1030 1039.
11. Silva JA, White CJ, Collins TJ, et al. Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina. Am Heart J 1998 136 : 156 163.
12. Ellis SG, Brener SJ, DeLuca S, et al. Late myocardial ischemic events after saphenous vein graft intervention-importance of initially "nonsignificant" vein graft lesions. Am J Cardiol 1997 79 : 1460 1464.
13. Price MJ, Sawhney N, Kao JA, et al. Clinical outcomes after sirolimus-eluting stent implantation for de novo saphenous vein graft lesions. Catheter Cardiovasc Interv 2005 65 : 208 211.
14. Hoye A, Lemos PA, Arampatzis CA, et al. Effectiveness of the sirolimus-eluting stent in the treatment of saphenous vein graft disease. J Invasive Cardiol 2004 16 : 230 233.
15. Tsuchida K, Ong AT, Aoki J, et al. Immediate and one-year outcome of percutaneous intervention of saphenous vein graft disease with paclitaxel-eluting stents. Am J Cardiol 2005 96 : 395 398.
16. Zahn R, Hamm CW, Schneider S, et al. Incidence and predictors of target vessel revascularization and clinical event rates of the sirolimus-eluting coronary stent (results from the prospective multicenter German Cypher Stent registry). Am J Cardiol 2005 95 : 1302 1308.
17. Win HK, Caldera AE, Maresh K, et al. Clinical outcomes and stent thrombosis following off-label use of drug-eluting stents. JAMA 2007 297 : 2001 2009.
18. Ruchin PE, Faddy SC, Muller DW, et al. Clinical follow-up of paclitaxel-eluting (TAXUS) stents for the treatment of saphenous vein graft disease. J Interv Cardiol 2007 20 : 258 264.
19. Ge L, Iakovou I, Sangiorgi GM, et al. Treatment of saphenous vein graft lesions with drug-eluting stents: Immediate and midterm outcome. J Am Coll Cardiol 2005 45 : 989 994.
20. Lee MS, Shah AP, Aragon J, et al. Drug-eluting stenting is superior to bare metal stenting in saphenous vein grafts. Catheter Cardiovasc Interv 2005 66 : 507 511.
21. Chu WW, Rha SW, Kuchulakanti PK, et al. Efficacy of sirolimus-eluting stents compared with bare metal stents for saphenous vein graft intervention. Am J Cardiol 2006 97 : 34 37.
22. Hoffmann R, Pohl T, Koster R, et al. Implantation of paclitaxel-eluting stents in saphenous vein grafts: Clinical and angiographic follow-up results from a multicentre study. Heart 2007 93 : 331 334.
23. Wohrle J, Nusser T, Kestler HA, et al. Comparison of the slow-release polymer-based paclitaxel-eluting Taxus-Express stent with the bare-metal Express stent for saphenous vein graft interventions. Clin Res Cardiol 2007 96 : 70 76.
24. Chu WW, Kuchulakanti PK, Wang B, et al. Efficacy of sirolimus-eluting stents as compared to paclitaxel-eluting stents for saphenous vein graft intervention. J Interv Cardiol 2006 19 : 121 125.
25. Rocca HP, Kaiser C, Pfisterer M. Targeted stent use in clinical practice based on evidence from the BAsel Stent Cost Effectiveness Trial (BASKET). Eur Heart J 2007 28 : 719 725.
26. Vermeersch P, Agostoni P, Verheye S, et al. Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: Six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial. J Am Coll Cardiol 2006 48 : 2423 2431.
27. Vermeersch P, Agostoni P, Verheye S, et al. Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: Results from the randomized DELAYED RRISC trial. J Am Coll Cardiol 2007 50 : 261 267.
28. Ellis SG. Crying fire in a theater" or a "confirmatory sighting? J Am Coll Cardiol 2007 50 : 268 269.
29. Pache J, Kastrati A, Mehilli J, et al. Intracoronary stenting and angiographic results: Strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol 2003 41 : 1283 1288.
30. Pache J, Dibra A, Mehilli J, et al. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: A prospective, randomized trial. Eur Heart J 2005 26 : 1262 1268.
31. Tung R, Kaul S, Diamond GA, et al. Narrative review: Drug-eluting stents for the management of restenosis: A critical appraisal of the evidence. Ann Intern Med 2006 144 : 913 919.
32. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet 2005 366 : 921 929.
33. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007 356 : 998 1008.
34. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: Data from a large two-institutional cohort study. Lancet 2007 369 : 667 678.
35. Lagerqvist B, James SK, Stenestrand U, et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007 356 : 1009 1019.
36. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA 2007 297 : 159 168.
37. Stankovic G, Colombo A, Presbitero P, et al. Randomized evaluation of polytetrafluoroethylene-covered stent in saphenous vein grafts: The Randomized Evaluation of polytetrafluoroethylene COVERed stent in Saphenous vein grafts (RECOVERS) trial. Circulation 2003 108 : 37 42.
38. Schachinger V, Hamm CW, Munzel T, et al. A randomized trial of polytetrafluoroethylene-membrane-covered stents compared with conventional stents in aortocoronary saphenous vein grafts. J Am Coll Cardiol 2003 42 : 1360 1369.
39. Grines CL, Bonow RO, Casey DE Jr., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: A science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. J Am Coll Cardiol 2007 49 : 734 739.
40. Cutlip DE, Windecker S, Mehran R, et al. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation 2007 115 : 2344 2351.